Seres Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Seres Therapeutics, Inc.
MaaT Pharma’s replacement bacterial ecosystem for the gastro-intestinal tract, MaaT103, has shown promise in top-line data from a Phase II study in patients with refractory aGvHD, energizing the microbiome field.
The Korean microbiome therapeutics developer KoBioLabs will launch a domestic IPO later this month and hopes to grow into a top three global company in the sector by 2025, helped by licensing deals.
The public biotech’s first foray into the microbiome started well, but a clinical trial failure followed by a success has now left Seres with both regulatory and commercial issues.
After years of halting progress in its microbiome-based pipeline, 4D Pharma has produced promising early data from its cancer immunotherapy combination.
- Drug Discovery Tools
- Large Molecule
- Other Names / Subsidiaries
- Seres Health, Inc.